Limiting side effects from Luxturna treatment
Researchers discovered a method to reduce Luxturna injection-related inflammation, improving safety and potentially preventing chorioretinal atrophy.
Search results
Researchers discovered a method to reduce Luxturna injection-related inflammation, improving safety and potentially preventing chorioretinal atrophy.
Tuesday 29 October, 7.00pm - 8.30pm - via Zoom - Come and join us to celebrate the first anniversary of our Men's Peer Support Group and to promote Men's Health Awareness Month.
Saturday 16 November 2024, 12.30pm - In-person - Come and join Rachael and the group for lunch at Revolution, Oxford Road in Manchester.
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
We are nothing without our amazing community. They are the reason we do what we do and are a constant source of inspiration to us.
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our amazing volunteers are diverse in age, background and ethnicity. The one thing they have in common is that they are all living with, or directly affected by, an inherited sight loss condition.
The project aims to develop a cost effective method of examining the entire ABCA4 gene to look for variations that might cause disease.
Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.